Market access in digital health is the work of turning a cleared, built and clinically credible product into one that someone in the U.S. will pay for, prescribe and keep using. Regulatory authorization is one step on that road. Coverage, reimbursement or direct contracts, clinical evidence and the infrastructure for patients and providers to actually use the product are the rest. Founders who treat them as one project, led by clinical credibility, reach revenue faster than those who treat them as a series of hand-offs. This is the kind of clinical and commercial leadership we provide as a Fractional Chief Medical Officer for healthcare SaaS and digital health companies.
This guide is written for founders, executives and the investors who back them. It covers what market access means for software-based care, how payers and providers decide, what changed in 2025 and 2026, and how to sequence a strategy.
TL;DR
- FDA authorization does not by itself deliver patient access. A 2024 peer-reviewed review describes full access as regulatory authorization, value assessment, pricing and reimbursement, and patient-access infrastructure.
- U.S. digital health products reach buyers through several pathways, including self-pay, employer programs, reimbursement, direct contracting and licensing. Pick the pathway before you build the evidence plan.
- Payers increasingly ask for randomized trials, comparison with standard care and local-population data. Providers ask about interoperability, workflow fit and implementation capacity.
- Coverage is uneven across commercial, Medicare and Medicaid plans, so a payer-by-payer plan beats a single national assumption.
- Investors can test a portfolio company's access plan with five questions, listed below.
Table of Contents
- What market access means for a digital health company
- Why FDA clearance is not the finish line
- The five questions payers and health systems ask
- The coverage landscape: uneven by design
- What changed in 2025 and 2026
- Choosing the pathway: a direct-contracting example
- A sequence for building a U.S. market access strategy
- For investors: five questions for a portfolio company
- Our perspective
- Work with a healthcare advisory team
- FAQ
- Sources
What market access means for a digital health company
In pharma, market access is largely about price and formulary position. In digital health the term is broader, because software can be sold in more ways than a drug can. The DTx Alliance, a digital therapeutics trade body, lays out multiple pathways by which products reach patients and clinicians: self-pay, employer programs, reimbursement, direct contracting, clinical-service models, licensing and outsourced services. Which pathways fit depends on the product.
The same document separates market access from patient access. A product may need a clinician prescription, third-party authorization, patient selection, or some combination. So there are two questions to answer:
- Market access: Who pays, under what rules, and on what evidence?
- Patient access: Who is allowed to start a patient on the product, and how does that patient actually get it running?
A product can pass the first test and fail the second. A covered tool that clinicians cannot fit into a visit will stay unused.
Why FDA clearance is not the finish line
The 2024 review is direct on this point: in the United States, FDA clearance does not necessarily achieve automatic patient access. Comprehensive approaches typically add value assessment, pricing and reimbursement, and patient-access infrastructure. The authors describe that infrastructure as covering technical usability, education, equity and post-market surveillance, and note that market-access potential alone does not ensure patient uptake.
For a startup this changes the order of work. Many teams finish the regulatory strategy, then discover the buyer wants evidence the pivotal study never collected. A better habit is to write the access hypothesis first: who is the economic buyer, which clinician orders or recommends the product, and what outcome does each of them need to see. Regulatory strategy, study design and the pricing model then follow from that hypothesis.

The five questions payers and health systems ask
IQVIA's Digital Health Trends 2025 report summarizes what U.S. buyers look for. Payers increasingly expect randomized controlled trials, comparison with standard care and evidence from a local population. Published health-economic studies remain scarce, so payers also weigh real-world impact such as resource use and provider workload. Providers focus on interoperability, workflow fit and the ability to implement.
Translated into the questions a buyer asks in a meeting:
- Does it work, versus what we do today? Comparison with standard care, not with no care.
- Does it work for our members or patients? Local-population relevance matters, particularly for Medicaid and regional plans.
- What does it change in cost or utilization? Resource use and avoided events, in numbers.
- What does it do to my clinicians' day? Provider workload is a cost line for health systems.
- Can we turn it on? Integration with the EHR, training and support.
The fifth question is where many otherwise strong products stall. If it applies to you, our guide to EHR integration strategy for SaaS startups explains why starting from clinical workflow shortens the work. Our piece on payer value propositions and evidence checks goes deeper on questions one through three.
The coverage landscape: uneven by design
The volume of billing codes can look reassuring. IQVIA reports that U.S. digital health and digital-care use is supported by more than 300 billing codes, including 117 for software-based technologies. Having a code is not the same as being paid for it.
The American Medical Association's issue brief on commercial payer coverage of digital-medicine CPT codes found:
- a lack of alignment among commercial, Medicare and Medicaid coverage;
- inconsistent commercial adoption and variable transparency;
- different payer review timelines;
- most commercial payers covering remote patient monitoring, with less consistent coverage of newer remote therapeutic monitoring, eConsult and eVisit codes;
- limited utilization of most new digital-medicine codes, tied to inconsistent coverage, nascent evidence, equipment and data-management requirements, and the operational infrastructure needed to run remote monitoring.
The practical lesson: model access payer by payer and code by code, with a realistic review timeline for each. A revenue forecast that assumes uniform national coverage is a forecast that will miss. If your product depends on remote monitoring codes, our guides to RPM CPT codes, RTM CPT codes and EHR steps and CCM CPT codes cover the billing detail your provider customers will ask about.
What changed in 2025 and 2026
Several federal moves affect how a digital health company plans its route to market. Dates matter here, and the official pages are the place to confirm the current status before you act on any of them.
| Development | What it says | Why it matters for access |
|---|---|---|
| FDA Clinical Decision Support guidance, January 2026 | Explains which CDS functions meeting the statutory criteria in section 520(o)(1)(E) of the FD&C Act are excluded from the device definition. Functions that remain devices stay under FDA digital-health policies. | Determines whether a clinical software feature needs a device pathway at all, which changes timeline and evidence burden. |
| FDA General Wellness guidance, January 6, 2026 | States FDA does not intend to examine low-risk general-wellness products for device premarket and postmarket requirements when they meet the guidance's conditions. | Clarifies where consumer and employer wellness offerings sit, and where a clinical claim moves a product out of that space. |
| CMS ACCESS Model, began July 5, 2026 | A 10-year model testing recurring outcome-aligned payments in Original Medicare for technology-supported care for hypertension, diabetes, chronic musculoskeletal pain and depression. | A payment design built around outcomes rather than visits, relevant to any product in those four conditions. |
| CMS guidance on digital mental-health treatment devices, March 2026 | An FDA-cleared or De Novo-authorized device may be furnished incident to ongoing behavioral-health services when prescribed or ordered by the billing practitioner, who incurs its cost as a supply. | Defines a Medicare route for this device class, and who must be the customer. |
| FDA draft AI-device guidance, January 2025 | Recommends lifecycle controls across design, development, maintenance, documentation and postmarket performance monitoring. It is draft guidance, not a final rule. | A useful planning frame for AI-enabled products, to be tracked until finalized. |
The ACCESS Model deserves the closest reading from founders in the four named conditions. Its design points to where payment is heading: recurring, tied to outcomes, and dependent on technology-supported care. That puts a premium on outcome data you can actually measure and report.
Choosing the pathway: a direct-contracting example
Traditional reimbursement is not the only road. The AMA's case study of Oshi Health illustrates a direct payer and employer contracting pathway. Oshi uses bundled assessment and treatment payments, outcome-linked installments, and a monthly fee for ongoing care, rather than relying only on traditional reimbursement.
The model is instructive for what it requires, not just for what it avoids: a clinical service that can define a bundle, outcomes a payer will accept as the basis for installments, and a contract that matches how the buyer budgets. Direct contracting still runs on evidence and clinical credibility. It moves the negotiation from a code to a contract.
IQVIA's report adds that developers are diversifying business models, consolidating around focused segments, and expanding horizontally or vertically to address stakeholder needs and improve commercialization. Narrow focus with a clear buyer tends to beat broad positioning at the access stage.

A sequence for building a U.S. market access strategy
There is no single correct order, but this one avoids the most expensive rework. At each step we note where a Fractional Chief Medical Officer or advisory engagement does the work for you.
Step 1: Define the clinical problem and the buyer
Name the condition, the care setting and the person who pays for the status quo. A payer, an employer, a health system and a physician group each value different outcomes. Write one sentence for each buyer on what changes for them. Where it goes wrong: a product pitched at "healthcare" in general. Our clinical strategy work starts here, and the clinical strategy guide for digital health companies shows the approach.
Step 2: Settle the regulatory position early
Decide whether your functions are device functions, fall under the CDS exclusion criteria or sit within general-wellness policy, using the FDA guidance above. The answer sets your evidence burden and your claims language. Where it goes wrong: marketing language that implies a clinical claim the regulatory position does not support. We provide regulatory guidance as part of our advisory services, so claims and clinical positioning are reviewed together.
Step 3: Match the pathway to the product
Use the DTx Alliance pathway list as a menu: self-pay, employer, reimbursement, direct contracting, clinical-service model, licensing. Score each against your product, your buyer and your cash runway. Reimbursement can take longer than a direct contract; self-pay may be fast but narrow. Pick one lead pathway and one fallback.
Step 4: Build the evidence package for that buyer
Work backward from the five buyer questions. If payers want comparison with standard care and local-population evidence, design the study to deliver both. Capture resource-use and provider-workload data from the start, because those are the measures payers fall back on when formal economic studies are scarce. Where it goes wrong: a study that proves efficacy but cannot support a value argument. Our payer value proposition guide lists the evidence checks we apply.
Step 5: Prepare the provider-side operations
Coverage fails without delivery. The AMA notes equipment, data-management and operational requirements as constraints on provider uptake of remote monitoring. Map the clinical workflow, the staffing it needs, the EHR connection and the training. This is clinical operations work, and it is one of the services we offer.
Step 6: Test readiness before you spend on sales
Before a sales push or a raise, check whether your FDA position, payer fit and operational story hold together. Our U.S. healthtech market readiness guide describes the assessment, and market readiness assessment is a service we deliver.
Step 7: Sequence payers and monitor the rules
Start with the payers or employers where your evidence is strongest, build reference accounts, and plan for different review timelines at each. Recheck the federal pages above on a schedule, since guidance and models change.
For investors: five questions for a portfolio company
An access plan can be checked in one meeting. Ask the management team:
- Who is the economic buyer, and who is the clinical decision-maker? Are they the same person?
- Which pathway leads, and what is the fallback?
- What evidence does that buyer require, and what share of it exists today?
- What is the realistic review timeline at the first three target payers, and how is it reflected in the cash plan?
- Who owns the clinical and regulatory narrative day to day? Is it someone with a clinical background, or is it split across a CEO and a sales lead?
Weak answers to the last question are common in early-stage companies, and it is where fractional medical leadership closes the gap. We provide investor support and executive and board advising alongside Fractional CMO work, so a portfolio company gets one clinical voice across product, regulatory and payer conversations.
Our perspective
Most of the access problems we see described in the research are not market problems. They are sequencing problems. Teams build the product, then the evidence, then look for a buyer, when the buyer's questions should have shaped the first two.
A physician who has also run the business side reads a payer's evidence request differently from a founder reading it for the first time. That dual view is why our model is built around direct access to an advisor with both clinical and business expertise. Paul Bergeron has over 25 years in medicine and business, grounded in real patient care and startup growth.
Our view is simple. Put clinical leadership into the access plan on day one. A Fractional Chief Medical Officer can own the clinical narrative, review the regulatory position, shape the evidence plan and speak to payers and health systems as a physician. That is the gap a fractional CMO is built to close. If something in your access plan feels misaligned, I would welcome a conversation.
Paul Bergeron MD, MBA
Work with a healthcare advisory team
The StartUp MD is a healthcare advisory firm for healthcare SaaS and digital health companies. We offer Fractional Chief Medical Officer leadership and advisory services covering clinical strategy, product evaluation, regulatory guidance, clinical operations consulting, market readiness assessment and investor support. Engagements run as advisory projects or as fractional executive retainers. See the Fractional CMO and advisory services we offer, or start from The StartUp MD.

For investors, the same services support portfolio companies preparing for a raise, a payer pilot or a diligence process.
FAQ
What is the difference between market access and patient access in digital health?
Market access concerns who pays and under what terms: coverage, reimbursement, contracts and pricing. Patient access concerns how a patient actually gets the product, which may require a clinician prescription, third-party authorization or patient selection, according to the DTx Alliance. You need both, and the infrastructure for patient access includes usability, education and equity.
Does FDA clearance guarantee that payers will cover my product?
No. A 2024 review notes that FDA clearance does not necessarily achieve automatic patient access. Payers run their own value assessments and have their own review timelines, and coverage varies across commercial, Medicare and Medicaid plans.
What evidence do U.S. payers want from digital health companies?
According to IQVIA's 2025 report, payers increasingly expect randomized controlled trials, comparison with standard care and local-population evidence. Because published health-economic studies are scarce, they also look at real-world resource use and provider workload.
Is the CMS ACCESS Model relevant to my company?
It is if your product supports care for hypertension, diabetes, chronic musculoskeletal pain or depression in Original Medicare. The model began July 5, 2026, runs 10 years and tests recurring outcome-aligned payments. Check the CMS page for current participation details.
When should a startup bring in a Fractional CMO for market access?
Before the evidence plan and the regulatory position are fixed, since both shape what buyers will accept. A fractional CMO provides physician-level leadership on clinical strategy, regulatory guidance and payer conversations without a full-time executive hire.
Sources
- DTx Market and Patient Access Pathways, DTx Alliance
- Core elements of national policy for digital health, PMC
- Digital Health Trends 2025, IQVIA Institute
- Commercial Payer Coverage for Digital Care, AMA issue brief
- Future of Health Case Study: Oshi Health, AMA
- Clinical Decision Support Software, FDA
- General Wellness: Policy for Low Risk Devices, FDA
- ACCESS Model, CMS Innovation Center
- Medicare & Mental Health Coverage, CMS MLN1986542
- FDA draft guidance for AI-enabled medical devices
